Projet RACKHAM : étude de la radiosensibilité des patients atteints de neurofibromatose de type 1 (NF1), résultats finaux
P. Combemale(Centre Léon Bérard), Nicolas Foray(Inserm), S. Pinson(Hôpital Edouard Herriot), A. C. B. Granzoto(Inserm), Clément Devic(Inserm), Mélanie L. Ferlazzo(Inserm), Laurène Sonzogni(Inserm)
Cited by 0
Related Papers
Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial
|The Lancet Oncology|2015|432
Long‐term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42‐month analysis of the phase II randomized, double‐blind BOLT study
|British Journal of Dermatology|2019|197
Translocation, t(17;22)(q22;q13), in dermatofibrosarcoma protuberans: a new tumor-associated chromosome rearrangement
|Cytogenetics and Cell Genetics|2008|194
Long‐term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30‐month analysis of the randomized phase 2 BOLT study
|Journal of the European Academy of Dermatology and Venereology|2017|192
Neurofibromatosis 1 French national guidelines based on an extensive literature review since 1966
|Orphanet Journal of Rare Diseases|2020|188